Which beta‑blocker is most commonly used in pregnant patients with hyperthyroidism?

Metoprolol is the Beta-Blocker Recommended for Pregnant Patients with Hyperthyroidism

The Endocrine Society guidelines specifically recommend metoprolol as the beta-blocker of choice in pregnant patients with hyperthyroidism, particularly for symptomatic management of hyperemesis gravidarum-associated thyrotoxicosis 1.

Guideline-Based Recommendation

The 2012 Endocrine Society Clinical Practice Guideline explicitly states that "Beta blockers such as metoprolol may be helpful and may be used with obstetrical agreement" for pregnant women with hyperemesis gravidarum and clinical hyperthyroidism 1. This represents a USPSTF Level B recommendation, though the evidence quality is noted as poor.

Clinical Context and Rationale

When Beta-Blockers Are Used in Pregnancy:

• Primary indication: Symptomatic relief in women with significant thyrotoxic symptoms, particularly those with hyperemesis gravidarum who appear significantly thyrotoxic or have elevated total T3 values 1
• Not for routine use: Most women with hyperemesis gravidarum and suppressed TSH do not require antithyroid drug treatment or beta-blockers 1
• Short-term therapy: Beta-adrenergic blockade provides short-term symptomatic relief while definitive management is initiated 2

Why Metoprolol Over Propranolol:

While older literature from the 1970s-1990s describes propranolol use in pregnancy 3, 4, 5, the current guideline preference for metoprolol likely reflects its beta-1 selectivity, which theoretically reduces effects on uterine and peripheral vascular beta-2 receptors. The cardioselective property may offer a better safety profile during pregnancy, though direct comparative data in pregnant patients is limited.

Important Caveats:

• Obstetrical agreement required: Beta-blocker use should be coordinated with obstetrics 1
• Limited evidence base: The recommendation carries poor evidence quality, reflecting the paucity of controlled trials in pregnant populations 1
• Adjunctive therapy only: Beta-blockers address symptoms but do not treat the underlying hyperthyroidism; antithyroid drugs (propylthiouracil in first trimester, then methimazole) remain the mainstay of treatment for Graves' disease 6, 2
• Duration: Use should be limited to the period needed for symptom control and until antithyroid drugs achieve therapeutic effect

Practical Application:

For a pregnant patient with symptomatic hyperthyroidism:

1. Assess severity of thyrotoxic symptoms (tachycardia, tremor, anxiety)
2. If significantly symptomatic, initiate metoprolol with obstetrical consultation
3. Use lowest effective dose for symptom control
4. Simultaneously initiate appropriate antithyroid drug therapy (PTU in first trimester)
5. Taper beta-blocker as thyroid function normalizes with definitive treatment